Introduction to, and classification of, the systemic vasculitides

Best Practice and Research: Clinical Rheumatology

Volumn 15, Issue 2, 2001, Pages 187-202

  Luqmani, Raashid A ^a   Robinson, Helen ^a  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Anti neutrophil cytoplasmic antibody; Churg Strauss syndrome; Classification; Cryoglobulinaemia; Epidemiology; Giant cell arteritis; Henoch Schonlein purpura; Hepatitis B; Hepatitis C; Kawasaki disease; Microscopic polyangiitis; Polyarteritis nodosa; Takayasu's arteritis; Vasculitis; Wegener's granulomatosis

Indexed keywords

ANTIVIRUS AGENT; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; NEUTROPHIL CYTOPLASMIC ANTIBODY; STEROID;

CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CLINICAL PRACTICE; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; GLOMERULONEPHRITIS; HUMAN; MICROSCOPY; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; REVIEW; SYSTEMIC VASCULITIS; TISSUE NECROSIS; VALIDATION PROCESS; VASCULAR DISEASE; WEGENER GRANULOMATOSIS;

EID: 0034988336     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1053/berh.2001.0139     Document Type: Article

References (69)

1. Uber eine bisher nicht beschreibene eigenthumliche Arteriener Krankung (periarteritis nodosa) Die mit Morbus Brightii und rapid fortschreitender allgemeiner Muskellahmung einhergeht
2. Vasculitis in rheumatoid arthritis
3. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham study
4. Mortality by cardiovascular disease and use of corticosteroids in RA
5. The significance of vascular inflammation in rheumatoid arthritis
6. The pathogenesis of atherosclerosis: A perspective for the 1990s
7. Roles of infectious agents in atherosclerosis and restenosis
8. Is vasculitis a significant component of atherosclerosis?
9. Prognostic factors in polyarteritis
10. Antibodies against neutrophils and monocytes: Tools for diagnosis and marker of disease activity in Wegener's Granulomatosis
11. Systemic vasculitis in the 1980s - Is there an increasing incidence of Wegener's granulomatosis and microscopic polyarteritis?
12. Systematic vasculitis in a district general hospital 1972-1980: Clinical and laboratory features, classification and prognosis of 80 cases
13. Epidemiology of systemic vasculitis. A ten-year study
14. Primary renal vasculitis in Norfolk - Increasing incidence or increasing recognition?
15. Systemic vasculitis in adults in Northwestern Spain, 1988-1997: Clinical and epidemiologic aspects
16. Primary vasculitis in a Norwegian community hospital: A retrospective study
17. The incidence of rheumatoid vasculitis in the Norwich Health Authority
18. Trimethoprim-sulfamethoxazole (Cotrimoxazole) for the prevention of relapses of Wegener's granulomatosis
19. Association of chronic nasal carriage of staphylococcus aureus and higher relapse rates in Wegener's granulomatosis
20. Seasonal variation in the onset of Wegener's granulomatosis, polyarteritis nodosa and giant cell arteritis
21. The epidemiology of Wegener's Granulomatosis: Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources
22. Wegener's granulomatosis: Role of environmental exposures
23. Molecular approaches for identification of infectious agents in Wegener's granulomatosis
24. Treatment of polyarteritis nodosa related to hepatitis B virus with short-term steroid therapy associated with antiviral agents and plasma exchanges. A prospective trial in 33 patients
25. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients
26. Interferon-alpha in mixed cryoglobulinaemia patients. A randomised crossover-controlled trial
27. Association between silica exposure and necrotizing crescentic glomerulonephritis with p-ANCA and anti-MPO antibodies: A hospital-based case-control study
28. Occupational exposure to crystalline silica and autoimmune disease
29. Churg Strauss syndrome: Possible role of environmental factors
30. Alpha I-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis
31. Systemic necrotizing vasculitides in severe alpha I-antitrypsin deficiency
32. Temporal artery biopsy: A diagnostic tool for systemic necrotizing vasculitis
33. Giant-cell granuloma of the respiratory tract (Wegener's Granulomatosis)
34. Relapses in patients with a systemic vasculitis
35. Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's Granulomatosis Classification Criteria Cohort
36. Clinical findings and prognosis of polyarteritis nodosa and Churg Strauss angiitis: A study in 165 patients
37. European Vasculitis Study Group. A multi-centre randomised controlled trial of cyclophosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis (CYCAZAREM)
38. Polyarteritis and the kidney
39. Outcome of end-stage renal disease in patients with rare causes of renal failure. III. Systemic/vascular disorders
40. Wegener's granulomatosis: An analysis of 158 patients
41. Damage occurs early in systemic vasculitis and is an index of outcome
42. Periarteritis nodosa: A critical review
43. Nomenclature and classification of vasculitis: Plus ca change, plus c'est la meme chose
44. Nomenclature of systemic vasculitides: Proposal of an international consensus conference
45. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction
46. A comparison of two nomenclature systems for primary systemic vasculitis
47. Uber generalisierte septische Gefasserkrankungen
48. Outcome of polyarteritis nodosa and Churg-Strauss syndrome: An analysis of twenty-five patients
49. Microscopic polyarteritis: Presentation, pathology and prognosis
50. Renal involvement in Churg-Strauss syndrome
51. Anti-neutrophil cytoplasmic antibodies, abnormal angiograms and pathological findings in polyarteritis nodosa and Churg-Strauss syndrome: Indications for the classification of vasculitides of the polyarteritis nodosa group
52. Antiproteinase 3-and antimyeloperoxidase-associated vasculitis
53. ANCA-associated glomerulonephritis: Relationship of main ANCA subtypes to renal outcome, age and sex of the patients
54. European therapeutic trials in ANCA-associated systemic vasculitis: Disease scoring, consensus regimens and proposed clinical trials
55. Long-term follow-up of polyarteritis nodosa, microscopic polyangiitis and Churg Strauss syndrome: Analysis of 4 prospective trials including 278 patients
56. Limited forms of angiitis and granulomatosis of Wegener's type
57. Classical versus non-renal Wegener's granulomatosis
58. Wegener's granulomatosis: Anatomic correlates a proposed classification
59. A prospective study of vasculitis patients collected in a five year period: Evaluation of the Chapel Hill nomenclature
60. A role for hepatitis C virus infection in type II cryoglobulinaemia
61. Giant cell arteritis in Jerusalem: A 12-year epidemiological study
62. Wegener's Granulomatosis - Increased incidence or interested recognition?
63. Epidemiology of systemic vasculitis: Changing incidence or definition?
64. Disease pattern in cranial and large-vessel giant cell arteritis
65. Wegener's granulomatosis associated with vasculitis of the temporal artery
66. Effect of classification on the incidence of polyarteritis nodosa and microscopic polyangiitis
67. Polyarteritis nodosa and microscopic polyangiitis
68. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis
69. The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis